Imagion Biosystems

Imagion Biosystems Inventory

The Inventory of Imagion Biosystems (IBX.AX) as of Nov 13, 2026 is 315,122.00 AUD. In the previous year, Inventory was 174,534.00 AUD — a change of 80.55% (higher).

Inventory

315,122.00AUD

YoY

80.55%

Last updated:

Inventory of Imagion Biosystems is 2022 315,122.00 AUD. Inventory of Imagion Biosystems was 2021 174,534.00 AUD. It decreases by 80.55% higher compared to the previous year.

The Imagion Biosystems Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2017
340,555.00 AUD
Jan 1, 2018
-355,136.00 AUD
Jan 1, 2019
97,977.00 AUD
Jan 1, 2020
64,092.00 AUD
Jan 1, 2021
174,534.00 AUD
Jan 1, 2022
315,122.00 AUD
The Imagion Biosystems Inventory history
YEARInventoryYoY
315,122.00AUD+80.55%
174,534.00AUD+172.32%
64,092.00AUD-34.58%
97,977.00AUD-127.59%
-355,136.00AUD-204.28%
340,555.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imagion Biosystems Stock analysis

What does Imagion Biosystems do? Imagion Biosystems Ltd develops non-radioactive diagnostic imaging technology through its MagSense and PrecisionMRX product lines. MagSense uses cancer-specific magnetic nanoparticles for detecting breast, prostate, and ovarian cancers, with a Phase I clinical study ongoing for its HER2 imaging agent. PrecisionMRX offers coated nanoparticles including Dextran-Coated, mPEG Coated, Oleic Acid Coated, and Carboxylic Acid Functionalized variants for magnetic relaxometry applications. The company generates revenue primarily through research and development activities, focusing on advanced cancer diagnostics and medical imaging solutions. The firm operates exclusively in the Research and Development segment, targeting medical professionals and healthcare institutions requiring innovative diagnostic tools. MagSense technology is designed as an injectable solution tailored to specific cancer types, while PrecisionMRX nanoparticles serve biomedical applications demanding high precision. These products are developed for use in cancer diagnostics, with clinical studies validating their effectiveness in detecting critical diseases. Imagion Biosystems' revenue streams derive from the development and commercialization of its proprietary imaging technologies. The company's MagSense platform enables functional imaging for cancer detection without radioactive materials, appealing to healthcare providers seeking safer diagnostic alternatives. PrecisionMRX nanoparticles support specialized biomedical applications, offering customizable solutions for medical imaging needs across various cancer types. Imagion Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imagion Biosystems stock

Inventory of Imagion Biosystems is 315,122.00 AUD in 2022.

Inventory of Imagion Biosystems changed from 174,534.00 AUD to 315,122.00 AUD, representing a 80.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Imagion Biosystems since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Imagion Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Imagion Biosystems

All Key Metrics — Imagion Biosystems